Procter & Gamble 10-Q 2025-09-30

Filed 2025-10-24. 8 sections, 150K characters. Original on sec.gov · Markdown · JSON

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

xTrueQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2025

OR

oFalseTRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

pglogoa21.jpg

THE PROCTER & GAMBLE COMPANY

(Exact name of registrant as specified in its charter)

OhioOH1-43431-0411980
(State of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
One Procter & Gamble PlazaCincinnatiOH
One Procter & Gamble Plaza, Cincinnati, Ohio45202
(Address of principal executive offices)(Zip Code)

(513) 983-1100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Common Stock, without Par ValuePGNYSE
0.110% Notes due 2026PG26DNYSE
3.250% EUR Notes due 2026PG26FNYSE
4.875% EUR Notes due May 2027PG27ANYSE
1.200% Notes due 2028PG28NYSE
3.150% EUR Notes due 2028PG28BNYSE
1.250% Notes due 2029PG29BNYSE
1.800% Notes due 2029PG29ANYSE
6.250% GBP Notes due January 2030PG30NYSE
0.350% Notes due 2030PG30CNYSE
0.230% Notes due 2031PG31ANYSE
3.250% EUR Notes due 2031PG31BNYSE
5.250% GBP Notes due January 2033PG33NYSE
3.200% EUR Notes due 2034PG34CNYSE
1.875% Notes due 2038PG38NYSE
0.900% Notes due 2041PG41NYSE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filerþAccelerated filer¨
Non-accelerated filer¨Smaller reporting company¨False
Emerging growth company¨False

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ False

There were 2,336,733,549 shares of Common Stock outstanding as of September 30, 2025.

FORM 10-Q TABLE OF CONTENTSPage
PART IItem 1.Financial Statements1
Consolidated Statements of Earnings1
Consolidated Statements of Comprehensive Income1
Consolidated Balance Sheets2
Consolidated Statements of Shareholders' Equity3
Consolidated Statements of Cash Flows4
Notes to Consolidated Financial Statements5
Note 1: Basis of Presentation5
Note 2: New Accounting Pronouncements and Policies5
Note 3: Segment Information5
Note 4: Goodwill and Intangible Assets7
Note 5: Earnings Per Share8
Note 6: Share-Based Compensation and Postretirement Benefits9
Note 7: Risk Management Activities and Fair Value Measurements9
Note 8: Accumulated Other Comprehensive Income/(Loss)11
Note 9: Commitments and Contingencies11
Note 10: Supplier Finance Programs12
Note 11: Restructuring Program12
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations13
Item 3.Quantitative and Qualitative Disclosures About Market Risk24
Item 4.Controls and Procedures24
PART IIItem 1.Legal Proceedings24
Item 1A.Risk Factors24
Item 2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities24
Item 5.Other Information25
Item 6.Exhibits26
Signature27

The Procter & Gamble Company 1

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS

Three Months Ended September 30
Amounts in millions except per share amounts20252024
NET SALES$22,386$21,737
Cost of products sold10,88710,421
Selling, general and administrative expense5,6435,519
OPERATING INCOME5,8565,797
Interest expense(197)(238)
Interest income108135
Other non-operating income/(expense), net268(554)
EARNINGS BEFORE INCOME TAXES6,0345,140
Income taxes1,2531,152
NET EARNINGS4,7813,987
Less: Net earnings attributable to noncontrolling interests3128
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE$4,750$3,959
NET EARNINGS PER COMMON SHARE (1)
Basic$2.00$1.65
Diluted$1.95$1.61

(1)Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Three Months Ended September 30
Amounts in millions20252024
NET EARNINGS$4,781$3,987
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation(20)1,026
Unrealized gains/(losses) on investment securities(2)2
Unrealized gains/(losses) on defined benefit postretirement plans3(21)
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX(19)1,007
TOTAL COMPREHENSIVE INCOME4,7624,994
Less: Comprehensive income attributable to noncontrolling interests2428
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE$4,737$4,965

See accompanying Notes to Consolidated Financial Statements.

2 The Procter & Gamble Company

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

Amounts in millionsSeptember 30, 2025June 30, 2025
Assets
CURRENT ASSETS
Cash and cash equivalents$11,171$9,556
Accounts receivable6,4876,185
INVENTORIES
Materials and supplies2,0722,022
Work in process1,0411,012
Finished goods4,7354,516
Total inventories7,8487,551
Prepaid expenses and other current assets1,6122,100
TOTAL CURRENT ASSETS27,11825,392
PROPERTY, PLANT AND EQUIPMENT, NET24,11923,897
GOODWILL41,64341,650
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET21,81821,910
OTHER NONCURRENT ASSETS12,90112,381
TOTAL ASSETS$127,599$125,231
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable$15,609$15,227
Accrued and other liabilities10,75611,318
Debt due within one year11,6319,513
TOTAL CURRENT LIABILITIES37,99536,058
LONG-TERM DEBT24,31524,995
DEFERRED INCOME TAXES5,8935,774
OTHER NONCURRENT LIABILITIES5,8446,120
TOTAL LIABILITIES74,04872,946
SHAREHOLDERS’ EQUITY
Preferred stock770777
Common stock – shares issued –September 20254,009.2
J

Showing the first 8K of 63K characters. Open the full section

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may appear throughout this report, including without limitation, in the following sections: “Management's Discussion and Analysis,” “Risk Factors” and "Notes 4 and 9 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.

Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial risks, including foreign currency fluctuations, changes in global interest rates and rate differentials, currency exchange, or pricing controls and tariffs; (2) the ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share repurchases and dividend payments; (3) the ability to successfully manage uncertainties related to changing political and geopolitical conditions and potential implications such as exchange rate fluctuations, market contraction, boycotts, variability and unpredictability in trade relations, sanctions, tariffs or other trade controls; (4) the ability to manage disruptions in credit markets or to our banking partners or changes to our credit rating; (5) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to various factors, including ones outside of our control, such as natural disasters, acts of war or terrorism or disease outbreaks; (6) the ability to successfully manage cost fluctuations and pressures, including prices of commodities and raw materials and costs of labor, transportation, energy, pensions and healthcare; (7) the ability to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy, packaging content, supply chain practices, social or environmental practices or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third-party information and operational technology systems, networks and services and maintain the security and functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage the demand, supply and operational challenges, as well as governmental responses or mandates, associated with a disease outbreak, including epidemics, pandemics or similar widespread public health concerns; (13) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits, evolving digital marketing and selling platform requirements and technological advances attained by, and patents granted to, competitors; (14) the ability to successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and financial objectives, without impacting the delivery of base business objectives; (15) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational changes while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of skilled or experienced employees may be limited; (16) the ability to successfully manage current and expanding regulatory and legal requirements and matters (including, without limitation, those laws, regulations, policies and related interpretations involving product liability, product and packaging composition, manufacturing processes, intellectual property, labor and employment, antitrust, privacy, cybersecurity, data protection and data transfers, artificial intelligence, tax, the environment, due diligence, risk oversight, accounting and financial reporting) and to resolve new and pending matters within current estimates; (17) the ability to manage changes in applicable tax laws and regulations; and (18) the ability to continue delivering progress towards our environmental sustainability ambitions. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from those projected herein is included in the section titled "Economic Conditions and Uncertainties" and the section titled "Risk Factors" (Part II, Item 1A) of this Form 10-Q.

Purpose, Approach and Non-GAAP Measures

The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of operations and cash flows by focusing on changes in certain key measures from year to year. The

Amounts in millions of dollars except per share amounts or as otherwise specified.

14 The Procter & Gamble Company

MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and accompanying Notes.

The MD&A is organized in the following sections:

  • Overview

  • Summary of Results – Three Months Ended September 30, 2025

  • Economic Conditions and Uncertainties

  • Results of Operations – Three Months Ended September 30, 2025

  • Segment Results – Three Months Ended September 30, 2025

  • Liquidity and Capital Resources

  • Measures Not Defined by U.S. GAAP

Throughout the MD&A we refer to measures used by management to evaluate performance, including unit volume growth, net sales, net earnings, diluted net earnings per common share (diluted EPS) and operating cash flow. We also refer to a number of financial measures that are not defined under U.S. GAAP, consisting of organic sales growth, Core earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the end of the MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to the most directly comparable U.S. GAAP measure.

Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the availability and comparability of

Showing the first 8K of 61K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in the Company’s exposure to market risk since June 30, 2025. Additional information can be found in Note 9, Risk Management Activities and Fair Value Measurements, of the Company's Form 10-K for the fiscal year ended June 30, 2025.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s Chairman of the Board, President and Chief Executive Officer, Jon R. Moeller, and the Company’s Chief Financial Officer, Andre Schulten, performed an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (Exchange Act)) as of the end of the period covered by this report.

Messrs. Moeller and Schulten have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (2) accumulated and communicated to our management, including Messrs. Moeller and Schulten, to allow their timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the Company’s fiscal quarter ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters and tax. In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State or local law when a governmental authority is a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold ($1 million or more).

There were no material changes during the quarter ended September 30, 2025, to our disclosure in Part I, Item 3, “Legal Proceedings” of our Form 10-K for the fiscal year ended June 30, 2025. There were no relevant matters to disclose under this Item for this period.

Item 1A. Risk Factors

For information on risk factors, please refer to "Risk Factors" in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended June 30, 2025.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

ISSUER PURCHASES OF EQUITY SECURITIES

PeriodTotal Number of Shares Purchased (1)Average Price Paid per Share (2)Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (3)Approximate Dollar Value of Shares That May Yet Be Purchased Under Our Share Repurchase Program
7/01/2025 - 7/31/20252,819,273$159.55—(3)
8/01/2025 - 8/31/20254,032,558154.994,032,558(3)
9/01/2025 - 9/30/20253,991,667156.583,991,667(3)
Total10,843,498$156.768,024,225(3)

(1)All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to satisfy tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third party and does not repurchase stock in connection with cashless exercises.

(2)Average price paid per share for open market transactions excludes commission.

(3)In accordance with the repurchase program announced on July 29, 2025, the Company reaffirmed in its earnings release on October 24, 2025, that it expects to reduce outstanding shares through direct share repurchases at a value of approximately $5 billion in fiscal year 2026, notwithstanding any purchases under the Company's compensation and benefit plans. Purchases may be made in the open market and/or private transactions and purchases may be increased, decreased or discontinued at any time without prior notice. The share repurchases are authorized pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a combination of operating cash flows and issuance of debt.

The Procter & Gamble Company 25

Item 5. Other Information

During the three months ended September 30, 2025, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.

26 The Procter & Gamble Company

Item 6. Exhibits

3.1Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the Board of Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June 30, 2016)
3.2Regulations (as approved by the Board of Directors on December 13, 2022, pursuant to authority granted by shareholders at the annual meeting on October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company’s Current Report on Form 8-K filed December 13, 2022)
4.1Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (Incorporated by reference to Exhibit (4-1) of the Company's Annual Report on Form 10-K for the year ended June 30, 2015)
10.1The Procter & Gamble Company 2025 Stock and Incentive Compensation Plan*+
10.2Short-Term Achievement Reward Program*+
10.3Performance Stock Program Summary*+
10.4Long-Term Incentive Program Summary*+
10.5Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2025 Stock and incentive Compensation Plan, The Procter & Gamble 2019 Stock and Incentive Compensation Plan and The Procter & Gamble 2014 Stock and Incentive Compensation Plan.*+
10.6Retirement Plan Restoration Program Summary*+
10.7Form of STAR Stock Option Award Agreement*+
10.8Form of Director Annual RSU Award Agreement*+
10.9Form of Director Annual RSU Award Agreement (Deferred)*+
10.10Form of Director RSU Award Agreement (Quarterly Fees)*+
10.11Form of PSU Award Agreement*+
10.12Form of Deferred PSU Award Agreement*+
10.13Form of LTIP RSU Award Agreement*+
10.14Form of LTIP Stock Option Award Agreement*+
10.15Form of Special RSU Award Agreement*+
10.16Form of Retirement Restoration Plan RSU Award Agreement*+
31.1Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1Section 1350 Certifications – Chief Executive Officer +
32.2Section 1350 Certifications – Chief Financial Officer +
101.SCH (1)Inline XBRL Taxonomy Extension Schema Document
101.CAL (1)Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF (1)Inline XBRL Taxonomy Definition Linkbase Document
101.LAB (1)Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE (1)Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

The Procter & Gamble Company 27

*Compensatory plan or arrangement
+Filed herewith
(1)Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

THE PROCTER & GAMBLE COMPANY
October 24, 2025/s/ MATTHEW W. JANZARUK
Date(Matthew W. Janzaruk)
Senior Vice President - Chief Accounting Officer (Principal Accounting Officer)